Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors

Hong, Dongsheng; Bi, Ling; Zhou, Jun; Tong, Ying; Zhao, Qiu; Chen, Jing; Lu, Xin-Jiang

doi:10.18632/oncotarget.17194

Cited by 16 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer (BC) is one of the most common malignancies and a leading cause of cancer death among women worldwide (Kwon et al, 2015;Hong et al, 2017;Zhang et al, 2017). Indeed invasive BC is the most frequently diagnosed cancer and leading cause of cancer-related death in young women, with invasive ductal carcinoma being the most common pathological type (Lebeau et al, 2014;Siegel et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Transcription Factor Profiling to Predict Recurrence-Free Survival in Breast Cancer: Development and Validation of a Nomogram to Optimize Clinical Management

Chen

Yang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer-related death in young women. Several prognostic and predictive transcription factor (TF) markers have been reported for BC; however, they are inconsistent due to small datasets, the heterogeneity of BC, and variation in data pre-processing approaches. This study aimed to identify an effective predictive TF signature for the prognosis of patients with BC. We analyzed the TF data of 868 patients with BC in The Cancer Genome Atlas (TCGA) database to investigate TF biomarkers relevant to recurrence-free survival (RFS). These patients were separated into training and internal validation datasets, with GSE2034 and GSE42568 used as external validation sets. A nine-TF signature was identified as crucially related to the RFS of patients with BC by univariate Cox proportional hazard analysis, least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and multivariate Cox proportional hazard analysis in the training dataset. Kaplan-Meier analysis revealed that the nine-TF signature could significantly distinguish high-and low-risk patients in both the internal validation dataset and the two external validation sets. Receiver operating characteristic (ROC) analysis further verified that the nine-TF signature showed a good performance for predicting the RFS of patients with BC. In addition, we developed a nomogram based on risk score and lymph node status, with C-index, ROC, and calibration plot analysis, suggesting that it displays good performance and clinical value. In summary, we used integrated bioinformatics approaches to identify an effective predictive nine-TF signature which may be a potential biomarker for BC prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Transcription Factor Profiling to Predict Recurrence-Free Survival in Breast Cancer: Development and Validation of a Nomogram to Optimize Clinical Management

Chen

Yang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Moreover, joint stiffness was reported in 44% of the patients enrolled in the study. A recent meta-analysis exploring menopausal symptoms in postmenopausal women showed a 17.9% rate of arthralgia, ranging from 5.25 to 54.29% in the studies included [ 67 ]. Of note, the incidence of arthralgia was significantly decreased in early-stage breast cancer compared with advanced disease (RR = 0.34, 95% CI: 0.16−0.75) [ 67 ].…”

Section: Discussionmentioning

confidence: 99%

“…A recent meta-analysis exploring menopausal symptoms in postmenopausal women showed a 17.9% rate of arthralgia, ranging from 5.25 to 54.29% in the studies included [ 67 ]. Of note, the incidence of arthralgia was significantly decreased in early-stage breast cancer compared with advanced disease (RR = 0.34, 95% CI: 0.16−0.75) [ 67 ]. Overall, approximately 20–47% of women develop musculoskeletal symptoms during AI therapy, according to previous studies, which is consistent with our results.…”

Section: Discussionmentioning

confidence: 99%

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review

Andrikopoulou

Fiste

Liontos

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Treatment with aromatase inhibitors (AIs) is fundamental in women with hormone receptor-positive breast cancer in the adjuvant as well as the metastatic setting. Even though it is considered to be a well-tolerated therapy, aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) is the most common adverse event encountered by breast cancer patients. CDK4/6 inhibitors have emerged as a new treatment strategy in metastatic hormone receptor-positive breast cancer. However, the impact of CDK4/6 inhibitors on musculoskeletal symptoms caused by AIs is not well-defined. Objectives: This systematic review aims to identify the frequency of joint symptoms induced by treatment with AIs and CDK4/6 inhibitors in the metastatic setting. Search strategy: Eligible articles were identified by a search of existing literature for the period 2005/01/01–2021/01/01; The algorithm consisted of a predefined combination of the following keywords “breast”, “cancer”, “aromatase inhibitors”, “CDK4/6”, “phase III”. Selection criteria: This study was performed in accordance with PRISMA guidelines. All randomized controlled Phase III trials (RCTs) evaluating the administration of third-generation aromatase inhibitors (AIs) and CDK4/6 inhibitors in postmenopausal women in the metastatic setting were considered eligible for this review. Data collection: Overall, 16 randomized control trials (RCTs) were retrieved, of which nine studies explored the administration of AIs in the metastatic setting and seven studies investigated the combination of CDK4/6 inhibitors and AIs. Arthralgia was reported in 1–47% of patients treated with AIs and 5.8–33.3% of patients treated with CDK4/6 inhibitors. Myalgias occurred in 2–23.7% of patients receiving AIs compared with 4.8–11.9% of patients treated with CDK4/6 inhibitors. The incidence of back pain was 7–32.9% vs. 2.9–8.5% in postmenopausal women with metastatic disease treated with AIs and CDK4/6 inhibitors, respectively. Bone pain was reported in 7–32.9% of postmenopausal women treated with AIs and 2.9–8.5% of women treated with CDK4/6 inhibitors. Conclusions: AI treatment-induced musculoskeletal syndrome is an adverse event affecting over one-third (20–47%) of postmenopausal patients treated with AIs that often leads to treatment discontinuation. Data from RCTs provide evidence that the incidence of musculoskeletal symptoms is relatively decreased upon CDK4/6 inhibitor administration. CDK4/6 inhibitors may provide a protective role against AIMSS development.

show abstract

“…4,[10][11][12][13] Selective serotonin reuptake inhibitors (SSRIs), a-adrenergic agonists, b-blockers, antidopaminergic agents, aromatase inhibitors, vitamin E, gabapentin, progesterone, thalidomide, black cohosh, and soy phytoestrogens have all been proposed but are generally not used due to lack of efficacy or side effects. 3,7,[14][15][16][17][18][19] Cannabinoids are commonly used for treatment of nausea, neuropathic pain, and anorexia in cancer patients. 20 Some studies support the use of nabilone, a synthetic analogue of 9tetrahydroxycannabinol (9-THC), in the treatment of night sweats in cancer patients as well.…”

Section: Introductionmentioning

confidence: 99%

Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases

Carr

Vertelney

Fronk

et al. 2019

Journal of Palliative Medicine

View full text Add to dashboard Cite

Background: Night sweats significantly impact the quality of life for cancer patients and are often resistant to treatment. Cannabinoids have been shown to modulate cytokine activity and produce hypothermia in animal models, suggesting that they may be a promising candidate for palliation of night sweats in patients with oncologic disease. Objective: Assess efficacy of the oral cannabinoid, dronabinol, for palliation of night sweats in cancer patients. Design: A retrospective record search identified five cancer patients who had tried oral dronabinol for palliation of their night sweats between 2013 and 2016 and subjectively reported on its efficacy. Setting/Subjects: A convenience sample of five patients from the outpatient consultative palliative medicine program at Stanford Medical Center was chosen from a search of past records. Patients were included if they had a cancer diagnosis and complained of night sweats that subjectively interfered with their quality of life. All agreed to try oral dronabinol for palliation of their night sweats. Measurements: Patients self-reported the effect of oral synthetic dronabinol on their night sweats. Results: Treatment of five patients with advanced cancer with synthetic orally administered dronabinol resulted in the successful management of persistent symptomatic paraneoplastic night sweats. Conclusion: Dronabinol and/or medicinal cannabis are promising therapies for palliation of night sweats in cancer patients.

show abstract

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors

Cited by 16 publications

References 56 publications

Transcription Factor Profiling to Predict Recurrence-Free Survival in Breast Cancer: Development and Validation of a Nomogram to Optimize Clinical Management

Transcription Factor Profiling to Predict Recurrence-Free Survival in Breast Cancer: Development and Validation of a Nomogram to Optimize Clinical Management

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review

Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases

Contact Info

Product

Resources

About